Immuno-Gene Therapy Committee

Aims & Scope

The Immuno-Gene Therapy Committee strives to:

• Assist in the planning of the annual meeting scientific program and the review of submitted abstracts in the cell and gene therapy category.
• Review the status of the immuno & gene therapy field and compile a list of major scientific issues that must be addressed to advance or enable cellular therapies utilizing immunotherapy and gene therapy.
• Publish position papers and engage in scientific discourse as necessary to advance the field.
  
  

Selected Publications

• A new breakthrough in genome editing: the story of Cagevy (2024)
  
  
• Synthetic Biology Approaches for Enhancing Safety and Specificity of CAR-T Cell Therapies for Solid Cancers (2024)
  
  
• (Editorial) 2023 Gene Therapy Mini Series (2023)
  
  
• Editing human hematopoietic stem cells: advances and challenges (2023)
  
  
• CRISPR/Cas9-mediated gene editing. A promising strategy in hematological disorders (2023)
  
  
• Emerging frontiers in immuno- and gene therapy for cancer (2023)
  
  
• ISCT survey on hospital practices to support externally manufactured investigational cell-gene therapy products (2022)
  
  
• Delivering externally manufactured cell and gene therapy products to patients: perspectives from the academic center experience (2022)

The Committee

Members

Alexey Bersenev, MD, PhD
Yale University
New Haven, United States

Jaap Jan Boelens, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, United States

Mitchell Cairo, MD
New York Medical College
New York, United States

Yoon Seok Choi, MD, PhD
Ajou University School of Medicine
Suwon, Republic of Korea

Andrew Fesnak, MD
University of Pennsylvania
Philadelphia, United States

Patrick Hanley, PhD
Children's National Hospital
Washington, DC, United States

Margaret Lamb, MD
Nationwide Children's Hospital
Columbus, United States

Dean Lee, MD, PhD
Nationwide Children's Hospital
Columbus, United States

Charlotte Hill Machado, PhD
IMPACT - Universidad de los Andes
Santiago, Chile
ESP Leadership Development Program

Shari Pilon-Thomas, PhD
Moffitt Cancer Center
Tampa, United States

Zulema Romero Garcia, PhD
University of California, Los Angeles
Los Angeles, United States

Branden Moriarity, PhD
University of Minnesota
Shoreview, United States

Nirali N. Shah, MD, MHSc
University of Minnesota
Shoreview, United States

Sandeep Soni, MD
CRISPR Therapeutics
San Francisco, USA

David Steffin, MD
Texas Children’s Hospital
Houston, United States

Piriya Yoganathan, PhD, MBA
Ottawa Hospital Research Institute
Ottawa, Canada
ESP Leadership Development Program